Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.

8/2/2019 Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.

1/21

1650717_1.doc

Charles P. Kennedy

Natalie RicherLERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, NJ 07090-1497Tel: 908.654.5000

Fax: 908.654.7866

OF COUNSELJosh Krevitt

Joseph Evall

Jacob SherkowGIBSON, DUNN & CRUTCHER LLP

200 Park Avenue

New York, NY 10166-0193Tel: 212.351.2490

Fax: 212.351.6390Michael Sitzman

GIBSON, DUNN & CRUTCHER LLP555 Mission Street, Suite 3000

San Francisco, CA 94105

Tel: 415.393.8221Fax: 415.374.8454

Attorneys for Plaintiffs Medicis Pharmaceutical Corporation

and Dow Pharmaceutical Sciences, Inc.

UNITED STATES DISTRICT COURT

DISTRICT OF NEW JERSEY

MEDICIS PHARMACEUTICAL CORPORATIONand DOW PHARMACEUTICAL SCIENCES, INC.

Plaintiffs,

v.

STIEFEL LABORATORIES, INC. andGLAXOSMITHKLINE PLC,

Defendants.

::

:

:

::

:

::

x

Document Filed Electronically

Civil Action No.

District Judge:Magistrate Judge:

COMPLAINT AND DEMAND FOR TRIAL BY JURY

Plaintiffs Medicis Pharmaceutical Corporation ("Medicis") and Dow Pharmaceutical

Sciences, Inc. ("Dow"), by their attorneys, allege as follows:


2/21

1650717_1.doc 2

THE PARTIES

1. Medicis is a Delaware corporation with its principal place of business at 7720North Dobson Road, Scottsdale, Arizona 85256.

2. Dow is a California corporation with its principal place of business at 1330Redwood Way, Petaluma, California 94954.

3. On information and belief, Defendant Stiefel Laboratories, Inc. ("Stiefel") isincorporated in Delaware, has its principal place of business in Coral Gables, Florida, and has its

headquarters at 20 T.W Alexander Drive Research Triangle Park, North Carolina 27709.

4. On information and belief, Stiefel conducts business operations in the UnitedStates, including in the State of New Jersey.

5. On information and belief, Defendant GlaxoSmithKline Plc ("GSK") whollyowns Stiefel.

6. On information and belief, GSK is incorporated in the United Kingdom and has aregistered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.

7. On information and belief, GSK conducts business operations throughout theUnited States, including in the State of New Jersey.

JURISDICTION

8. This action arises under 35 U.S.C. 271 and 281.9. This Court has subject matter jurisdiction over this action under 28 U.S.C.

1331 and 1338(a).

10. On information and belief, this Court has personal jurisdiction over Stiefelbecause Stiefel infringes United States Patent No. 6,387,383 (the '383 Patent) in this jurisdiction.

11. Venue is proper in this Court under 28 U.S.C. 1391(b) and (c).


3/21

1650717_1.doc 3

BACKGROUND

12. A copy of the 383 Patent is attached as Exhibit A.13. Dow is the owner by assignment of the '383 Patent, entitled "Topical

Low-Viscosity Gel Composition."

14. The 383 Patent is valid, unexpired, and duly issued by the U.S. Patent andTrademark Office.

15. Medicis is the exclusive licensee of the '383 Patent.16. One or more claims of the '383 Patent reads on a topical gel known as VeltinTM.17.

On information and belief, Stiefel makes, uses, offers to sell, sells, or imports

Veltin without authority of Plaintiffs.

18. On information and belief, Stiefel actively induces others to make, use, offer tosell, sell, or import Veltin without authority of Plaintiffs.

19. On information belief, Stiefel contributes to others making, using, offering to sell,selling, or importing Veltin without authority of Plaintiffs.

20. On information and belief, Stiefel willfully commits the acts described inparagraphs 17-19.

21. On information and belief, GSK makes, uses, offers to sell, sells, or importsVeltin.

22. On information belief, GSK actively induces others to make, use, offer to sell,sell, or import Veltin.

23. On information belief, GSK contributes to others making, using, offering to sell,selling, or importing Veltin.


4/21

1650717_1.doc 4

24. On information and belief, GSK willfully commits the acts described inparagraphs 21-23.

CLAIM I ____ INFRINGEMENT

(Against Stiefel)

25. Paragraphs 1-20 are incorporated by reference as if fully set forth herein.26. On information and belief, Stiefels making, use, offers to sell, sales, or

importation of VeltinTM directly infringes, literally or under the doctrine of equivalents, one or

more claims of the 383 Patent.

27. On information and belief, Stiefel actively induces others to infringe, literally orunder the doctrine of equivalents, one or more claims of the 383 Patent by manufacturing, using,

offering to sell, selling, or importing VeltinTM

.

28. On information and belief, Stiefel commits acts of contributory infringement,literally or under the doctrine of equivalents, of one or more claims of the 383 Patent by

manufacturing, using, offering to sell, selling, or importing VeltinTM.

CLAIM II ____ INFRINGEMENT

(Against GSK)

29. Paragraphs 1-24 are incorporated by reference as if fully set forth herein.30. On information and belief, GSKs making, use, offers to sell, sales, or importation

of VeltinTM directly infringes, literally or under the doctrine of equivalents, one or more claims

of the 383 Patent.

31. On information and belief, GSK actively induces others to infringe, literally orunder the doctrine of equivalents, one or more claims of the 383 Patent by manufacturing, using,

offering to sell, selling, or importing VeltinTM

.


5/21

1650717_1.doc 5

32. On information and belief, GSK commits acts of contributory infringement,literally or under the doctrine of equivalents, of one or more claims of the 383 Patent by

manufacturing, using, offering to sell, selling, or importing VeltinTM

.

RELIEF REQUESTED

Plaintiffs respectfully seek the following relief:

As to Claim I,

A. The entry of a judgment that Stiefels making, use, offers to sell, sales, orimportation of Veltin

TMdirectly infringes, induces infringement, or contributorily infringes one

or more claims of the 383 Patent;

B. An award of damages for Stiefels infringement of one or more claims of the 383Patent;

C. The entry of an injunction preventing Stiefel from further infringing one or moreclaims of the 383 Patent;

D. A declaration that this case is an exceptional and an award of increased damagesfor Stiefels willful infringement of one or more claims of the 383 Patent;

E. Pre- and post-judgment interest on any award of damages;F. Attorneys fees and costs pursuant to 35 U.S.C. 285 or as otherwise permitted

by law; and

G. Any other and further relief mandated by law or that this Court may deem just andproper.

And as to Claim II,

H. The entry of a judgment that GSKs manufacture, use, offers to sell, sales, orimportation of VeltinTM directly infringes, induces infringement, or contributorily infringes one

or more claims of the '383 Patent;


6/21

1650717_1.doc 6

I. An award of damages for GSKs infringement of one or more claims of the'383 Patent;

J. The entry of an injunction preventing GSK from further infringing one or moreclaims of the '383 Patent;

K. A declaration that this case is exceptional and an award of increased damages forGSKs willful infringement of one or more claims of the '383 Patent;

L. Pre- and post-judgment interest on any award of damages;M. Attorneys fees and costs pursuant to 35 U.S.C. 285 or as otherwise permitted

by law; and

N. Any other and further relief mandated by law or that this Court may deem just andproper.

JURY DEMAND

Plaintiffs demand a trial by jury on all issues so triable.

Respectfully submitted,

LERNER, DAVID, LITTENBERG,KRUMHOLZ & MENTLIK, LLP

Attorneys for Medicis Pharmaceutical

Corporation and Dow Pharmaceutical

Sciences , Inc.

Dated: March 20, 2012 By: s/ Charles P. KennedyCharles P. Kennedy

Tel: 908.654.5000

E-mail:[email protected]@ldlkm.com

OF COUNSEL:Josh Krevitt

Joseph Evall

Jacob Sherkow

Michael SitzmanGIBSON, DUNN & CRUTCHER LLP
mailto:[email protected]:[email protected]:[email protected]


7/21

1650717_1.doc 7

CERTIFICATION PURSUANT TO LOCAL CIVIL RULE 11.2

The undersigned hereby certifies, pursuant to Local Civil Rule 11.2, that with respect to

the matter in controversy herein, neither Medicis Pharmaceutical Corporation and DowPharmaceutical Sciences nor Medicis Pharmaceutical Corporation's and Dow Pharmaceutical

Sciences' attorney is aware of any other action pending in any court, or of any pending

arbitration or administrative proceeding, to which this matter is subject.

Dated: March 20, 2012 LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP

Attorneys for Plaintiffs Medicis

Pharmaceutical Corporation and Dow

Pharmaceutical Sciences, Inc.

By: s/ Charles P. Kennedy

Charles P. Kennedy

Tel: 908.654.5000E-mail: [email protected]

[email protected]


8/21

EXHIBIT A


9/21


10/21


11/21


12/21


13/21


14/21


15/21


16/21


17/21


18/21


19/21


20/21


21/21

Date post:	06-Apr-2018
Category:	Documents
Upload:	priorsmart
View:	221 times
Download:	0 times

Medicis Pharmaceutical et. al. v. Stiefel Laboratories et. al.

Documents